Shares of ChemoCentryx Inc. (NASDAQ:CCXI) dropped 3.4% on Tuesday . The stock traded as low as $4.16 and last traded at $4.22, with a volume of 113,417 shares changing hands. The stock had previously closed at $4.37.

CCXI has been the subject of several recent analyst reports. Zacks Investment Research upgraded ChemoCentryx from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research note on Wednesday, April 27th. Cowen and Company reiterated a “hold” rating on shares of ChemoCentryx in a research report on Thursday, May 19th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and issued a $11.00 price objective on shares of ChemoCentryx in a research report on Tuesday.

The company’s market capitalization is $175.83 million. The stock has a 50-day moving average price of $4.58 and a 200 day moving average price of $3.77.

ChemoCentryx (NASDAQ:CCXI) last released its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by $0.07. Equities analysts predict that ChemoCentryx Inc. will post ($0.50) earnings per share for the current year.

In other ChemoCentryx news, Director Geoffrey M. Parker purchased 40,000 shares of the stock in a transaction on Friday, May 13th. The shares were purchased at an average price of $4.03 per share, with a total value of $161,200.00. Following the completion of the transaction, the director now directly owns 13,514 shares in the company, valued at $54,461.42. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Thomas A. Edwards purchased 50,000 shares of the stock in a transaction on Tuesday, May 17th. The shares were acquired at an average cost of $4.05 per share, for a total transaction of $202,500.00. Following the transaction, the director now owns 91,977 shares of the company’s stock, valued at $372,506.85. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in ChemoCentryx stock. Westfield Capital Management Co. LP raised its position in ChemoCentryx Inc. (NASDAQ:CCXI) by 1.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,102,332 shares of the biopharmaceutical company’s stock after buying an additional 19,375 shares during the period. Westfield Capital Management Co. LP owned about 2.50% of ChemoCentryx worth $8,929,000 at the end of the most recent reporting period.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.